LUVOX CR Drug Patent Profile

When do Luvox Cr patents expire, and what generic alternatives are available?

Luvox Cr is a drug marketed by Jazz Pharms and is included in one NDA.

The generic ingredient in LUVOX CR is fluvoxamine maleate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the fluvoxamine maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Luvox Cr

A generic version of LUVOX CR was approved as fluvoxamine maleate by AIPING PHARM INC on November 29^th, 2000.

Summary for LUVOX CR

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for LUVOX CR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUVOX CR	Extended-release Capsules	fluvoxamine maleate	100 mg	022033	1	2009-04-20
LUVOX CR	Extended-release Capsules	fluvoxamine maleate	150 mg	022033	1	2009-04-13

US Patents and Regulatory Information for LUVOX CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms	LUVOX CR	fluvoxamine maleate	CAPSULE, EXTENDED RELEASE;ORAL	022033-001	Feb 28, 2008		DISCN	Yes	No
Jazz Pharms	LUVOX CR	fluvoxamine maleate	CAPSULE, EXTENDED RELEASE;ORAL	022033-002	Feb 28, 2008		DISCN	Yes	No

International Patents for LUVOX CR

See the table below for patents covering LUVOX CR around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2290027
Japan	2003500348
Algeria	3256	PREPARATIONS D'INHIBITEURS SPECIFIQUES DU RECAPTAGE DE LA SEROTONINE A LIBERATION MULTIPARTICULAIRE REGULEE

Investment Scenario and Fundamentals Analysis for LUVOX CR

Last updated: February 20, 2026

What is LUVOX CR?

LUVOX CR (fluvoxamine maleate extended-release) is a selective serotonin reuptake inhibitor (SSRI) indicated mainly for obsessive-compulsive disorder (OCD) and further approved in certain markets for off-label uses, including depression and anxiety. It is produced by Pfizer and distributed under the brand name Luvox CR.

Market Overview

The global SSRIs market was valued at approximately $11 billion in 2022, expected to grow at a CAGR of 3%. This includes sales of Luvox CR and competing drugs like fluoxetine, sertraline, and paroxetine.

The primary revenue driver for LUVOX CR hinges on its approved indications, especially OCD. Off-label use and expansion into new indications influence its sales growth potential.

Product Profile & Differentiators

• Dosage: Typically offers a 100 mg extended-release formulation, allowing once-daily dosing.
• Efficacy: Clinical trials indicate comparable efficacy to immediate-release fluvoxamine with improved tolerability due to gradual absorption.
• Patent & Exclusivity: Pfizer’s patent on LUVOX CR expired in 2020, leaving the drug facing generic competition. However, data exclusivity periods may extend slightly further.

Competitive Landscape

Drug	Therapy Class	Market Penetration	Patent Status	Launch Year	Approximate 2022 Sales
Fluoxetine (Prozac)	SSRI	Highest	Patent expired	1987	$1.2 billion [1]
Sertraline (Zoloft)	SSRI	High	Patent expired	1991	$1.0 billion [2]
Pindolol (off-label)	Other class	Moderate	N/A	1969	N/A
LUVOX CR (Pfizer)	SSRI	Moderate	Patent expired (2020)	1994	$200 million (2022) [3]

Post-patent expiry, sales decline for branded products typically lead to market share loss to generics. However, branded drugs may retain premium pricing if supported by unique formulations or brand loyalty.

Regulatory & Intellectual Property Considerations

• Patent Status: The patent expired in 2020, opening the market to generics.
• Data Exclusivity: In the U.S., data exclusivity lasted until 2025, preventing generic approval based solely on bioequivalence. This grants Pfizer limited time to maintain market share.
• Regulatory Approvals: Available in major markets, including the US, EU, and Japan, with marketing authorizations covering OCD and potentially off-label indications.

Financial Performance & Outlook

• Sales Trend (2019-2022): Peak sales in 2019 at approximately $300 million, declining sharply after patent expiry in 2020 due to generic competition.
• Forecast: Without new indications or formulations, sales are expected to plateau or decline further. However, potential for off-label use expansion or combination therapy could sustain modest revenues.

Investment Risks

• Generic Competition: Market share loss post-patent expiry decreases profitability.
• Off-Label Regulation: Use for unapproved indications carries risk of regulatory and legal challenges.
• Market Penetration: Saturation in primary indications limits growth.

Strategic Opportunities

• Development of New Uses: Clinical trials for new psychiatric or neurological indications can revive revenue.
• Formulation Improvements: Developing novel delivery systems or combination products might extend patent life or create new revenue streams.
• Market Expansion: Entry into emerging markets, where antidepressant use is growing.

Conclusion

LUVOX CR faces significant headwinds from patent expiration and generic entry. Its future value depends on Pfizer's ability to develop new indications, maintain a foothold through formulations, or leverage off-label uses legally. Investment opportunities are limited unless Pfizer announces pipeline advancements or new patent protections.

Key Takeaways

• LUVOX CR's patent expired in 2020, leading to a sharp decline in sales.
• The drug's primary market is now saturated, with generics dominating most sales.
• Opportunities exist in research for new indications or formulations that could provide a revenue lift.
• The next 3-5 years will test Pfizer's strategy to maintain profitability from LUVOX CR amid generic competition.

FAQs

1. How long does Pfizer have exclusive marketing rights for LUVOX CR?

In the U.S., data exclusivity lasted until 2025, delaying generic approval based on bioequivalence studies.

2. Is LUVOX CR still profitable for Pfizer?

Current profitability has declined due to patent expiration and generic competition. Future profitability hinges on new indications and formulations.

3. Can LUVOX CR be used for indications outside OCD?

While primarily approved for OCD, clinicians sometimes prescribe it off-label for depression and anxiety; regulatory approval is limited.

4. Are there clinical trials for new uses of fluvoxamine?

Yes, recent trials are exploring fluvoxamine’s role in COVID-19 and other inflammatory conditions, which could influence future revenues.

5. What is the competitive advantage over other SSRIs?

Limited. After patent expiry, LUVOX CR competes mainly on brand recognition and tolerability but faces stiff competition from generics.

---

References

[1] MarketWatch. (2023). Fluoxetine sales data.
[2] Statista. (2022). Sertraline market share and sales.
[3] Pfizer Annual Report. (2022). LUVOX CR sales figures.